Impact of N-acetylcysteine on cerebral amyloid-β plaques and kidney damage in spontaneously hypertensive stroke-prone rats

Journal of Alzheimer's Disease

Volumn 42, Issue , 2014, Pages S305-S313

  Bueche, Celine Zoe ^a   Garz, Cornelia ^b   Stanaszek, Luiza ^a   Niklass, Solveig ^b   Kropf, Siegfried ^b   Bittner, Daniel ^a,b   Härtig, Wolfgang ^c   Reymann, Klaus G ^a   Heinze, Hans Jochen ^a,b   Carare, Roxana O ^d   Schreiber, Stefanie ^a,b  

^a GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^b OTTO VON GUERICKE UNIVERSITY   (Germany)

^c UNIVERSITY OF LEIPZIG   (Germany)

^d UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Amyloid ; cerebral small vessel disease; hypertensive nephropathy; N acetylcysteine rats; spontaneously hypertensive stroke prone rats (SHRSP)

Indexed keywords

ACETYLCYSTEINE; AMYLOID BETA PROTEIN; IMMUNOGLOBULIN G; FIBRINOGEN RECEPTOR; FIBRONECTIN; LECTIN; SCAVENGER; VON WILLEBRAND FACTOR RECEPTOR;

AMYLOID PLAQUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BASAL GANGLION; BLOOD BRAIN BARRIER; CEREBROVASCULAR DISEASE; CONFERENCE PAPER; CONTROLLED STUDY; CORPUS CALLOSUM; ERYTHROCYTE; HIPPOCAMPUS; HISTOLOGY; IMMUNOHISTOCHEMISTRY; INTERSTITIAL NEPHRITIS; MALE; NONHUMAN; RAT; STROKE PRONE SPONTANEOUSLY HYPERTENSIVE RAT; THALAMUS; ANALYSIS OF VARIANCE; ANIMAL; BRAIN CORTEX; CEREBRAL SMALL VESSEL DISEASES; COMPLICATION; DIAGNOSTIC USE; DISEASE MODEL; DRUG EFFECTS; KIDNEY DISEASES; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PLAQUE, AMYLOID; SPONTANEOUSLY HYPERTENSIVE RAT;

ACETYLCYSTEINE; AMYLOID BETA-PEPTIDES; ANALYSIS OF VARIANCE; ANIMALS; BLOOD-BRAIN BARRIER; CEREBRAL CORTEX; CEREBRAL SMALL VESSEL DISEASES; DISEASE MODELS, ANIMAL; FIBRONECTINS; FREE RADICAL SCAVENGERS; KIDNEY DISEASES; LECTINS; MALE; PLAQUE, AMYLOID; PLATELET MEMBRANE GLYCOPROTEINS; RATS; RATS, INBRED SHR;

EID: 84907991376     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-132615     Document Type: Conference Paper

References (42)

1. Jokinen H, Gouw AA, Madureira S, Ylikoski R, van Straaten EC, van der Flier WM, Barkhof F, Scheltens P, Fazekas F, Schmidt R, Verdelho A, Ferro JM, Pantoni L, Inzitari D, Erkinjuntti T (2011) Incident lacunes influence cognitive decline: The LADIS study. Neurology 76, 1872-1878.
2. Lo RY, Jagust WJ (2012) Vascular burden and Alzheimer disease pathologic progression. Neurology 79, 1349-1355.
3. Wardlaw JM, Smith C, Dichgans M (2013) Mechanisms of sporadic cerebral small vessel disease: Insights from neuroimaging. Lancet Neurol 12, 483-497.
4. Yakushiji Y, Noguchi T, Hara M, Nishihara M, Eriguchi M, Nanri Y, Nishiyama M, Hirotsu T, Nakajima J, Kuroda Y, Hara H (2012) Distributional impact of brain microbleeds on global cognitive function in adults without neurological disorder. Stroke 43, 1800-1805.
5. Schreiber S, Bueche CZ, Garz C, Braun H (2013) Blood brain barrier breakdown as the starting point of cerebral small vessel disease?-New insights from a rat model. Exp Transl Stroke Med 5, 4.
6. Bailey EL, McCulloch J, Sudlow C, Wardlaw JM (2009) Potential animal models of lacunar stroke: A systematic review. Stroke 40, e451-e458.
7. Hainsworth AH, Markus HS (2008) Do in vivo experimental models reflect human cerebral small vessel disease? A systematic review. J Cereb Blood Flow Metab 28, 1877-1891.
8. Braun H, Bueche CZ, Garz C, Oldag A, Heinze HJ, Goertler M, Reymann KG, Schreiber S (2012) Stases are associated with blood-brain barrier damage and a restricted activation of coagulation in SHRSP. J Neurol Sci 322, 71-76.
9. Schreiber S, Bueche CZ, Garz C, Kropf S, Angenstein F, Goldschmidt J, Neumann J, Heinze HJ, Goertler M, Reymann KG, Braun H (2012) The pathologic cascade of cerebrovascular lesions in SHRSP: Is erythrocyte accumulation an early phase? J Cereb Blood Flow Metab 32, 278-290.
10. Braun H, Schreiber S (2013) Microbleeds in cerebral small vessel disease. Lancet Neurol 12, 735-736.
11. Grinberg LT, Thal DR (2010) Vascular pathology in the aged human brain. Acta Neuropathol 119, 277-290.
12. Meyrier A, Hill GS, Simon P (1998) Ischemic renal diseases: New insights into old entities. Kidney Int 54, 2-13.
13. NangakuM(2004) Mechanisms of tubulointerstitial injury in the kidney: Final common pathways to end-stage renal failure. Intern Med 43, 9-17.
14. Schreiber S, Bueche CZ, Garz C, Kropf S, Kuester D, Amann K, Heinze HJ, Goertler M, Reymann KG, Braun H (2011) Kidney pathology precedes and predicts the pathological cascade of cerebrovascular lesions in stroke prone rats. PloS One 6, e26287.
15. Bueche CZ, Hawkes C, Garz C,Vielhaber S, Attems J, Knight RT, Reymann K, Heinze H-J, Carare RO, Schreiber S (2014) Hypertension drives parenchymal beta-amyloid accumulation in the brain parenchyma. Ann Clin Transl Neurol 1, 124-129.
16. Schreiber S, Drukarch B, Garz C, Niklass S, Stanaszek L, Kropf S, Bueche C, Held F, Vielhaber S, Attems J, Reymann KG, Heinze H-J, Carare RO, Wilhelmus MM (2014) Interplay between age, cerebral small vessel disease, parenchymal amyloid-, and tau pathology: Longitudinal studies in hypertensive stroke-prone rats. J Alzheimers Dis. doi: 10.3233/JAD-132618.
17. Jagust W (2013) Vulnerable neural systems and the borderland of brain aging and neurodegeneration. Neuron 77, 219-234.
18. Attems J, Thal DR, Jellinger KA (2012) The relationship between subcortical tau pathology and Alzheimer's disease. Biochem Soc Trans 40, 711-715.
19. Attems J, Jellinger KA (2013) Amyloid and tau: Neither chicken nor egg but two partners in crime! Acta Neuropathol 126, 619-621.
20. Attems J, Jellinger K (2013) Neuropathological correlates of cerebral multimorbidity. Curr Alzheimer Res 10, 569-577.
21. Jellinger KA, Attems J (2012) Neuropathology and general autopsy findings in nondemented aged subjects. Clin Neuropathol 31, 87-98.
22. Jellinger KA, Attems J (2013) Neuropathological approaches to cerebral aging and neuroplasticity. Dialogues Clin Neurosci 15, 29-43.
23. Hawkes CA, Hartig W, Kacza J, Schliebs R, Weller RO, Nicoll JA, Carare RO (2011) Perivascular drainage of solutes is impaired in the ageing mouse brain and in the presence of cerebral amyloid angiopathy. Acta Neuropathol 121, 431-443.
24. WellerRO, Preston SD, Subash M, CarareRO(2009) Cerebral amyloid angiopathy in the aetiology and immunotherapy of Alzheimer disease. Alzheimers Res Ther 1, 6.
25. Zlokovic BV (2011) Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat Rev Neurosci 12, 723-738.
26. Carnevale D, Mascio G, D'Andrea I, Fardella V, Bell RD, Branchi I, Pallante F, Zlokovic B, Yan SS, Lembo G (2012) Hypertension induces brain beta-amyloid accumulation, cognitive impairment, and memory deterioration through activation of receptor for advanced glycation end products in brain vasculature. Hypertension 60, 188-197.
27. Csiszar A, Tucsek Z, Toth P, Sosnowska D, Gautam T, Koller A, Deak F, Sonntag WE, Ungvari Z (2013) Synergistic effects of hypertension and aging on cognitive function and hippocampal expression of genes involved in beta-amyloid generation and Alzheimer's disease. Am J Physiol Heart Circ Physiol 305, H1120-H1130.
28. Liu H, Xing A, Wang X, Liu G, Li L (2012) Regulation of beta-amyloid level in the brain of rats with cerebrovascular hypoperfusion. Neurobiol Aging 33, 826-842.
29. Ndung'u M, Hartig W, Wegner F, Mwenda JM, Low RW, Akinyemi RO, Kalaria RN (2012) Cerebral amyloid beta(42) deposits and microvascular pathology in ageing baboons. Neuropathol Appl Neurobiol 38, 487-499.
30. Bueche CZ, Garz C, Kropf S, Bittner D, Li W, Goertler M, Heinze HJ, Reymann K, Braun H, Schreiber S (2013) NAC changes the course of cerebral small vessel disease in SHRSP and reveals new insights for the meaning of stases-a randomized controlled study. Exp Transl Stroke Med 5, 5.
31. Tian N, Rose RA, Jordan S, Dwyer TM, Hughson MD, Manning RD Jr (2006) N-Acetylcysteine improves renal dysfunction, ameliorates kidney damage and decreases blood pressure in salt-sensitive hypertension. J Hypertens 24, 2263-2270.
32. Michalski D, Grosche J, Pelz J, Schneider D,Weise C, Bauer U, Kacza J, Gartner U, Hobohm C, HartigW(2010) A novel quantification of blood-brain barrier damage and histochemical typing after embolic stroke in rats. Brain Res 1359, 186-200.
33. Berndt MC, Andrews RK (2011) Thrombotic thrombocytopenic purpura: Reducing the risk? J Clin Invest 121, 522-524.
34. Chen J, Reheman A, Gushiken FC, Nolasco L, Fu X, Moake JL, Ni H, Lopez JA (2011) N-acetylcysteine reduces the size and activity of von Willebrand factor in human plasma and mice. J Clin Invest 121, 593-603.
35. Bell RD, Zlokovic BV (2009) Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease. Acta Neuropathol 118, 103-113.
36. Erickson MA, Hansen K, Banks WA (2012) Inflammationinduced dysfunction of the low-density lipoprotein receptorrelated protein-1 at the blood-brain barrier: Protection by the antioxidant N-acetylcysteine. Brain Behav Immun 26, 1085-1094.
37. Nicolakakis N, Aboulkassim T, Ongali B, Lecrux C, Fernandes P, Rosa-Neto P, Tong XK, Hamel E (2008) Complete rescue of cerebrovascular function in aged Alzheimer's disease transgenic mice by antioxidants and pioglitazone, a peroxisome proliferator-activated receptor gamma agonist. J Neurosci 28, 9287-9296.
38. Caglar Y, Ozgur H, Matur I, Yenilmez ED, Tuli A, Gonlusen G, Polat S (2013) Ultrastructural evaluation of the effect of Nacetylcysteine on methotrexate nephrotoxicity in rats. Histol Histopathol 28, 865-874.
39. Shalby AB, Assaf N, AhmedHH(2011) Possible mechanisms for N-acetyl cysteine and taurine in ameliorating acute renal failure induced by cisplatin in rats. Toxicol Mech Methods 21, 538-546.
40. Wang L, Wang Z, Liu J (2010) Protective effect of Nacetylcysteine on experimental chronic lead nephrotoxicity in immature female rats. Hum Exp Toxicol 29, 581-591.
41. Anfossi G, Russo I, Massucco P, Mattiello L, Cavalot F, Trovati M (2001) N-acetyl-L-cysteine exerts direct antiaggregating effect on human platelets. Eur J Clin Invest 31, 452-461.
42. Jepsen S, Hansen AB (1994) The influence of Nacetylcysteine on the measurement of prothrombin time and activated partial thromboplastin time in healthy subjects. Scand J Clin Lab Invest 54, 543-547.